港股異動 | 康哲藥業續漲超8%,日累計飆漲近40%
uSMART盈立智投3月18日消息,今日港股開盤,康哲藥業高開漲1.8%,隨後不斷拉昇飆漲,截至10:30,,康哲藥業盤中漲超9.46%,8個交易日累計飆升超40%。盤中最高價17.36港元,創2018年7月以來新高,總市值達429億港元。
康哲藥業16日公佈2020年止年度業績,營業額69.46億人民幣,按年增加14.4%;毛利51.34億元,上升12.9%。錄得純利25.3億元,增長29%,每股盈利1.0237元。末期息派20.33分。集團將着力整合皮膚醫美線的資源優勢,進一步豐富涵蓋處方藥、醫療器械和醫美護膚產品的完整皮膚醫美線產品矩陣,推動集團在皮膚醫美領域的縱深發展。此前,公司創新藥替拉珠單抗注射液中國註冊性試驗完成全部受試者入組。
截至2020年12月31日,該集團擁有超過20款創新等級高、市場潛力大、有競爭差異性優勢的創新產品,其中,9 款產品已在美國及(或)歐洲獲得上市批準,3款產品正處於中國註冊性試驗中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.